Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

NCT06681220 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT06681220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06681220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Lead sponsor
VA Office of Research and Development
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2026
Completion date
December 31, 2030
Enrollment
166 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent small cell lung cancer, relapsed small cell lung cancer